Artificial Intelligence
SenseTime
Computer-vision and deep-learning platform with proprietary IP across facial and image recognition, medical imaging, video analytics and autonomous driving.
A representative selection of investments made by China Everbright Group funds and by our own principal-investment book, spanning high technology, infrastructure, healthcare, consumer platforms, advanced manufacturing and real estate.
Holdings are grouped using the same sector taxonomy applied by the group’s investment committees. Realised positions are marked in the tags.
Computer-vision and deep-learning platform with proprietary IP across facial and image recognition, medical imaging, video analytics and autonomous driving.
Designs, manufactures and services premium smart electric vehicles, backed early in its development cycle by the group’s venture funds.
Develops silicon-based phased-array and digital beam-forming chips for satellite and near-satellite communications, with R&D teams in Israel and the United Kingdom.
Content-recommendation platform serving hundreds of billions of monthly recommendations to publishers and advertisers worldwide.
Bankcard acquiring and merchant payment processing across more than 330 prefecture-level cities, with a clearing and settlement network of national scale.
Albania’s principal airport. Route count and passenger traffic grew materially during the holding period; the fund exited in 2021 with a double-digit IRR.
Gas-fired cogeneration and wind-power operator with a diversified clean-energy portfolio, listed on the Hong Kong Stock Exchange (0579.HK).
One of the largest wind-turbine manufacturers in China, dual-listed in Shenzhen (002202.SZ) and Hong Kong (2208.HK).
Non-state provider of integrated oilfield services — reservoir study, drilling, completion and production enhancement — with operations across Central Asia, North America and the Middle East.
Chinese pharmaceutical innovator whose portfolio and pipeline address oncology, cardiovascular and metabolic disease, including the targeted oncology therapy icotinib.
Premium gynaecology, obstetrics and paediatrics network combining international clinical management systems with domestic care pathways.
Biopharmaceutical company developing compounds for rare and ultra-rare genetic diseases caused by nonsense mutations, including cystic fibrosis and cystinosis.
Leading Chinese video-entertainment platform, combining original content production with one of the country’s largest paid-membership bases.
Mobile-first cross-border marketplace targeting value-conscious consumers in Europe and North America, built on intelligent recommendation at scale.
One of the largest domestic players in China’s infant-formula and maternity nutrition market, with a product range spanning formula, rice flour and weaning foods.
World leader in nano-particle jetting for metal and ceramic additive manufacturing, holding more than fifty registered and pending patents.
Global supplier of intelligent test and measurement equipment, market leader in automotive end-of-line testing and expanding into life sciences and precision manufacturing.
Swiss producer of submicron and PVD-coated carbide inserts, specialising in universal Multi-Mat cutting tools for aerospace, automotive and general engineering.
Shandong-based manufacturer of ivory board and textile-tube paper, scaled from 120,000 tonnes of annual capacity at entry to a Hong Kong listing in 2007.
Flagship asset of a nationwide commercial retail brand, repositioned and refurbished after acquisition and later securitised as a listed real-estate ABS.
Former hotel in the mature Lidu business district, comprehensively refurbished into a park-facing workplace with amenity-led public space.
Fund-of-funds platform with aggregate commitments of RMB 17 billion, investing across opportunistic and value-add real-estate strategies.
Independent provider of high-end oilfield services and project management across evaluation, drilling, completion and production enhancement (2178.HK).
No holdings in this sector group.
Every logo below corresponds to a holding listed above. Company names and marks remain the property of their respective owners and are shown for identification only.
Positions are underwritten to a defined exit path — trade sale, listing or amortising cash flow — and monitored by a dedicated post-investment management team. Where our own balance sheet is committed, exposure is subject to the same credit-committee limits that govern our lending book.
We review proposals from sponsors, founders and fund managers whose plans intersect the Europe–Asia corridor.
Trademark notice. All company names, logos and trademarks shown on this page are the property of their respective owners and appear solely to identify portfolio holdings. Their use does not imply any endorsement of China Everbright Bank (Europe) S.A. Descriptions are summaries prepared for illustration; they are not offers, recommendations or investment advice, and past performance is not a guide to future returns. Image credits & licences →